<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) negative and EBV carrying Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) lines that remain phenotypically similar to the in vivo <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells (operationally defined group I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e>) express high levels of CD10 and CD77, and lack <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> markers such as CD23 and CD39, and the cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules CD11a, CD18, CD54 and CD58 </plain></SENT>
<SENT sid="1" pm="."><plain>This <z:mp ids='MP_0005384'>cell phenotype</z:mp> is associated with poor stimulatory capacity in allogeneic mixed lymphocytes cultures (MLC) [Avila-Carino et al </plain></SENT>
<SENT sid="2" pm="."><plain>Int </plain></SENT>
<SENT sid="3" pm="."><plain>J </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> 40, 691-697 (1987)] EBV carrying <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines tend to drift spontaneously towards an <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> phenotype in parallel with up-regulation of six EBV-encoded nuclear antigens (EBNA-2 to -6) and two membrane proteins (LMP-1 and -2) </plain></SENT>
<SENT sid="5" pm="."><plain>These <z:mp ids='MP_0001799'>viral</z:mp> antigens are characteristically expressed in <z:hpo ids='HP_0000001'>all</z:hpo> EBV transformed lymphoblastoid cell lines (LCLs) of <z:mpath ids='MPATH_458'>normal</z:mpath> B cell origin and can be induced in group I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines by treatment with the DNA demethylating agent <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> (5-azaC) [Masucci et al </plain></SENT>
<SENT sid="6" pm="."><plain>J </plain></SENT>
<SENT sid="7" pm="."><plain>Virol </plain></SENT>
<SENT sid="8" pm="."><plain>65, 1558-1567 (1989)] </plain></SENT>
<SENT sid="9" pm="."><plain>We have now studied the effect of 5-azaC on the induction of allogenic T cell proliferation by three EBV negative (Ramos, BL28 and BL41) and four EBV carrying <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines (Rael, Eli, Chep and Mutu) which stably express a group I phenotype </plain></SENT>
<SENT sid="10" pm="."><plain>Pre-treatment with 4-15 microM 5-azaC had no effect on the EBV negative cells but increased the stimulatory capacity of <z:hpo ids='HP_0000001'>all</z:hpo> four EBV carrying lines </plain></SENT>
<SENT sid="11" pm="."><plain>LMP-1 was the only <z:mp ids='MP_0001799'>viral</z:mp> antigen regularly induced suggesting that its expression may be required for the increase of allostimulation </plain></SENT>
<SENT sid="12" pm="."><plain>This was corroborated by the observation that LMP-1 transfection increased 35-70-fold the stimulatory capacity of Rael cells </plain></SENT>
<SENT sid="13" pm="."><plain>The cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule CD54 was the only cellular marker selectively up-regulated in <z:hpo ids='HP_0000001'>all</z:hpo> cell lines with increased stimulatory capacity </plain></SENT>
</text></document>